Dr. Rakesh Kumar Deepak is an accomplished immunologist and clinician with 11+ years of professional experience in clinical practice, research and academic leadership. He is currently serving as Additional Professor in the Department of Transplant Immunology & Immunogenetics at All India Institute of Medical Sciences, New Delhi (November 2016–Present), where he leads research initiatives, supervises postgraduate and doctoral students, and contributes to clinical service delivery in immunological diagnostics and transplant immunology.

Previously, he served as Senior Resident at AIIMS New Delhi (July 2013–July 2016), during which he completed his postgraduate training in Pathology and gained clinical expertise in immunological investigations and transplant-related immunological workup.

Research & Publications

Dr. Deepak has established a robust and multidisciplinary research profile spanning transplant immunology, immunogenetics, immunodeficiency disorders, infectious diseases (particularly tuberculosis), cancer immunology, and autoimmune conditions. His research output includes 21 peer-reviewed publications comprising 15 international journal articles and 3 national publications, covering original research and review articles in high-impact journals including Rheumatology, International Journal of Cancer, Asian Pacific Journal of Cancer Prevention, Chest Infections, Human Pathology and Neuromuscular Disorders. His research addresses critical clinical questions in allograft rejection, immune exhaustion in immunodeficiency disorders, HLA variation in autoimmune conditions, and immune checkpoint profiling in malignancies.

Patents & Scholarly Contributions

Dr. Deepak holds 1 US patent (Application Number 17783798, published 5 January 2023) titled "Device, System and Method for Real Time Monitoring and Analysis of Health Parameters Relating to Non-Communicable Diseases," developed in collaboration with leading clinical and research scientists. This patent demonstrates his engagement in translational research and innovation at the intersection of immunology and digital health.

Research Projects & Funding

Dr. Deepak is directing 3 major ongoing research projects as Principal Investigator with competitive funding from the Indian Council of Medical Research (ICMR) and AIIMS:

• Immune Exhaustion Signature in Indian Primary Immunodeficiency Disorders: Correlation with Clinical Severity and Hematopoietic Stem Cell Transplant Outcomes (ICMR, 3 years, 2026–2029, ₹96 Lakhs)
• Clinical Utility of Liquid Biopsy in Cardiac Allograft Rejection (ICMR, 3 years, 2023–2026, ₹98 Lakhs)
• Differentiating Monophasic from Recurrent/Progressive Pediatric Acquired Central Demyelination Syndromes with Special Focus on MOGAD (AIIMS, 2 years, 2026–2028, ₹20 Lakhs)

Additionally, he is serving as Co-Principal Investigator on 2 externally funded projects: Biomarker-Driven Precision Medicine: cfDNA and Exosomal Profiling in Renal Transplant Surveillance (ICMR, ₹1.4 Crore) and Profiling of Immune Checkpoint Inhibitors in Gallbladder Cancer (AIIMS, ₹10 Lakhs). His research portfolio demonstrates sustained competitiveness in securing large research grants and leadership in directing translational and clinical research with direct patient care implications.

Teaching & Academic Contributions

Dr. Deepak is actively involved in postgraduate and doctoral training. He is currently supervising 3 MD students and 1 PhD student, guiding the next generation of researchers and clinicians in immunology and related specialties. He also serves as Co-Guide and Doctoral Committee member for 5 departmental research projects spanning diverse immunological topics including autoimmune myopathies, celiac disease, hematopoietic stem cell transplantation, and renal transplantation.

Clinical Service & Patient Care Contributions

Dr. Deepak provides specialized clinical diagnostic services through the Cellular Immunology Division, offering free-of-cost immunological investigations for patients with primary and secondary immunodeficiency disorders. His service portfolio includes 14 specialized assays and diagnostic panels covering T cell and B cell frequency assessment, NK cell function, phagocytic disorders, chronic granulomatous disease, hyper-IgM syndrome, T cell function assays, and multisystem granulomatous disease (MSMD) diagnostics. These services are vital for establishing diagnoses and guiding clinical management of immunocompromised patients.

Collaborative Research & Professional Engagement

Dr. Deepak demonstrates strong collaborative research ethos through 5 ongoing collaborative projects with departments including Pathology, ENT and the Translational Institute of Internal Medicine (TII), and 6 completed collaborative projects involving pediatrics, medicine and other clinical departments. His collaborations span emerging areas such as celiac disease pathogenesis, tuberculosis immunobiology, vaccine development and integrated healthcare networks for non-communicable disease management.

Eligibility for Remarkable Professor Award

Dr. Rakesh Kumar Deepak demonstrates sustained excellence across multiple dimensions of academic and professional contribution. His 11+ years of clinical and academic service, 21 peer-reviewed publications in reputed international and national journals, 1 US patent, 3 major externally funded research projects as Principal Investigator, active mentorship of postgraduate and doctoral students, and comprehensive clinical diagnostic services for immunodeficiency patients collectively establish a strong profile of scholarly productivity and institutional contribution. His research focuses on clinically relevant questions in transplant immunology, immunodeficiency, and immune-oncology, with direct impact on patient care and outcomes.

Based on the achievements, credentials and contributions documented in the curriculum vitae, Dr. Rakesh Kumar Deepak is eligible for consideration for the Remarkable Professor Award in Scientific Laurels, particularly in recognition of his contributions to cutting-edge research in transplant and clinical immunology, mentorship of postgraduate researchers, translational innovation, and direct clinical service delivery to immunocompromised patient populations.